Parallel Advisors’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $63 | Hold |
200
| – | – | ﹤0.01% | 3991 |
|
|
2026
Q2 | $85 | Hold |
200
| – | – | ﹤0.01% | 3883 |
|
|
2026
Q1 | $160 | Hold |
200
| – | – | ﹤0.01% | 3760 |
|
|
2025
Q4 | $260 | Hold |
200
| – | – | ﹤0.01% | 3486 |
|
|
2025
Q3 | $252 | Hold |
200
| – | – | ﹤0.01% | 3422 |
|
|
2025
Q2 | $414 | Hold |
200
| – | – | ﹤0.01% | 3328 |
|
|
2025
Q1 | $440 | Hold |
200
| – | – | ﹤0.01% | 3253 |
|
|
2024
Q4 | $306 | Hold |
200
| – | – | ﹤0.01% | 3315 |
|
|
2024
Q3 | $398 | Hold |
200
| – | – | ﹤0.01% | 3214 |
|
|
2024
Q2 | $700 | Hold |
200
| – | – | ﹤0.01% | 3032 |
|
|
2024
Q1 | $554 | Hold |
200
| – | – | ﹤0.01% | 3037 |
|
|
2023
Q4 | $340 | Hold |
200
| – | – | ﹤0.01% | 3110 |
|
|
2023
Q3 | $206 | Sell |
200
-623
| -76% | -$887 | ﹤0.01% | 3228 |
|
|
2023
Q2 | $955 | Hold |
823
| – | – | ﹤0.01% | 2950 |
|
|
2023
Q1 | $1.24K | Buy |
823
+623
| +312% | +$1.56K | ﹤0.01% | 2903 |
|
|
2022
Q4 | $500 | Hold |
200
| – | – | ﹤0.01% | 3029 |
|
|
2022
Q3 | $1K | Hold |
200
| – | – | ﹤0.01% | 2922 |
|
|
2022
Q2 | $1K | Hold |
200
| – | – | ﹤0.01% | 2779 |
|
|
2022
Q1 | $1K | Hold |
200
| – | – | ﹤0.01% | 2761 |
|
|
2021
Q4 | $2K | Hold |
200
| – | – | ﹤0.01% | 2698 |
|
|
2021
Q3 | $2K | Hold |
200
| – | – | ﹤0.01% | 2690 |
|
|
2021
Q2 | $3K | Hold |
200
| – | – | ﹤0.01% | 2457 |
|
|
2021
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 2369 |
|
|
2020
Q4 | $4K | Hold |
200
| – | – | ﹤0.01% | 2096 |
|
|
2020
Q3 | $3K | Sell |
200
-122
| -38% | -$1.9K | ﹤0.01% | 2186 |
|
|
2020
Q2 | $4K | Buy |
322
+122
| +61% | +$2K | ﹤0.01% | 2011 |
|
|
2020
Q1 | $2K | Buy |
+200
| New | +$3.76K | ﹤0.01% | 2133 |
|
|
2019
Q2 | – | Sell |
-1,685
| Closed | -$41K | – | 2364 |
|
|
2019
Q1 | $41K | Buy |
1,685
+1,200
| +247% | +$31.4K | ﹤0.01% | 923 |
|
|
2018
Q4 | $12K | Buy |
+485
| New | +$13.3K | ﹤0.01% | 1246 |
|
|
2017
Q3 | – | Sell |
-250
| Closed | -$4K | – | 2147 |
|
|
2017
Q2 | $4K | Hold |
250
| – | – | ﹤0.01% | 1670 |
|
|
2017
Q1 | $4K | Hold |
250
| – | – | ﹤0.01% | 1577 |
|
|
2016
Q4 | $3K | Buy |
+250
| New | +$3.92K | ﹤0.01% | 1527 |
|
Other funds holding HRTX
Parallel Advisors's HRTX Position: Q3 2026 in Review
Parallel Advisors held its Heron Therapeutics (HRTX) position steady in Q3 2026 at 200 shares worth $63. The position accounts for ﹤0.01% of the portfolio, ranked #3991.
Parallel Advisors first reported a position in HRTX in Q4 2016 and has held it in 32 quarters since. The position peaked at $41K in Q1 2019. 49 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.
- Parallel Advisors held 200 shares of Heron Therapeutics worth $63 as of Q3 2026.
- Parallel Advisors left its Heron Therapeutics share count unchanged in Q3 2026.
- Heron Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3991 holding.
- Parallel Advisors first reported a position in Heron Therapeutics in Q4 2016 and has held it in 32 quarters since.
- Parallel Advisors's Heron Therapeutics position peaked at $41K in Q1 2019.
- 49 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.
Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.